Johnson & Johnson (JNJ)

$259.80 -2.01 (-0.77%)
Market Cap 624.74B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 23.66
Forward PE 22.13
Profit Margin 28.46%
Debt to Equity Ratio 0.44
Volume 5,650,123
Avg Vol 8,472,492
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 60%
Beta 0.24
Analysts Strong Sell
Price Target $275.42

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Tnitty4371
Tnitty4371 Aug. 11 at 3:36 PM
$AIHS 🎁🎁🎁💵💵💵📈📈📈 $PLAG $SPY $TSLA $JNJ
0 · Reply
HydrogenH2
HydrogenH2 Aug. 11 at 3:36 PM
$JNJ I guess next will be @ $250 ??
0 · Reply
TraderDaKing
TraderDaKing Aug. 11 at 3:35 PM
$ELTP $PFE $JNJ $LLY $MRNA THIS IS THE NEXT BIG STOCK IN Biopharmaceutical sector. Elite Pharmaceuticals is poised for a strong future with innovative drugs like SequestOx leading the way. Their robust pipeline and commitment to excellence position them as a standout in the pharmaceutical industry. Earnings for the fiscal period will be released Thursday, August 11, 2026. Join the conference call on Friday, August 12, 2026, at 11:30 AM EDT to hear the latest updates directly from the leadership team. For more information, visit their website at https://elitepharma.com/ Elite's ART technology will be the industry standard. ART™, is a multi-particulate capsule that contains an agonist in addition to naltrexone, an antagonist, used primarily in the management of alcohol dependence and drug dependence. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of drugs used today in pain management. ELITE WILL HELP SAVE THE WORLD.
0 · Reply
NRG8
NRG8 Aug. 11 at 3:07 PM
$AVGO $V $MA $JNJ $ABBV
0 · Reply
Wallstfan
Wallstfan Aug. 11 at 2:40 PM
$JNJ some wild price swings of late. Acting like tech stock. Can we just see $270 Geeze
1 · Reply
Matt_1
Matt_1 Aug. 11 at 2:32 PM
$CVRX $GSK $JNJ 👍
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Aug. 11 at 6:32 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
SniperAlphaCom
SniperAlphaCom Aug. 11 at 3:01 AM
$JNJ trade lifecycle update. TS Update #1 was shared with Elite members on June 25, followed by TS Update #2 on July 28. Price respected the updated trailing-stop area near $245, absorbed the pullback, and has now recovered to $261.81. The position remains active. This is why the stop follows structure—not every short-term fluctuation.
0 · Reply
OnlyFibs
OnlyFibs Aug. 11 at 2:19 AM
Johnson & Johnson $JNJ (2h) Bullish Flow: Institutional flow is slamming the Ask across long-dated leaps, including a massive $114.5K split sweep on January 2027 $290 Calls and $35.1K in August $272.50 Calls. Smart money is aggressively accumulating after $JNJ hit the $100.8B full-year revenue milestone while locking in a comprehensive $5.5B talc settlement to remove the primary legal overhang off the balance sheet. 🐂 💧 Bull Key Level: $262.50 (Bull confirmation to break the horizontal consolidation ceiling and launch a macro blue-sky continuation run) 🐂 🔥 Bear Key Level: $252.00 (Key structural support floor and ascending trendline anchor to defend) 🐻 ⚠️ Targets: $275.00 / $290.00 💰 🍺
0 · Reply
LiveTradePro
LiveTradePro Aug. 10 at 11:02 PM
$JNJ Good volume at the close Looks ready https://share.trendspider.com/chart/JNJ/6682nu5lwf
0 · Reply
Latest News on JNJ
Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Aug 10, 2026, 4:27 PM EDT - 1 day ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

2026-08-07T19:33:43.000Z - 4 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

CVX WMT

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

Aug 6, 2026, 6:23 PM EDT - 4 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

2026-08-06T10:48:29.000Z - 5 days ago

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

3 ‘Strong Buy’ Dividend Aristocrat Stocks for Dependable Income, 8/5/26

2026-08-05T18:48:12.000Z - 6 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks for Dependable Income, 8/5/26

IBM KO

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Aug 4, 2026, 4:05 PM EDT - 7 days ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

2026-08-04T12:50:51.000Z - 7 days ago

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 4, 2026, 8:45 AM EDT - 7 days ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Johnson & Johnson Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 8 days ago

Johnson & Johnson Transcript: Investor update

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

2026-08-03T11:00:29.000Z - 8 days ago

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

Johnson & Johnson removed from US Conviction List at Goldman Sachs

2026-08-03T09:35:43.000Z - 8 days ago

Johnson & Johnson removed from US Conviction List at Goldman Sachs

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Aug 2, 2026, 8:00 AM EDT - 9 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review

2026-07-30T12:35:46.000Z - 12 days ago

Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 30, 2026, 8:30 AM EDT - 12 days ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 6:13 PM EDT - 12 days ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:42 PM EDT - 13 days ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36

2026-07-29T21:40:31.000Z - 13 days ago

Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:38 PM EDT - 13 days ago

Johnson & Johnson lowers 2026 profit forecast

Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68

2026-07-29T21:35:31.000Z - 13 days ago

Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68

Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B

2026-07-29T21:35:19.000Z - 13 days ago

Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 5:28 PM EDT - 13 days ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Explainer: Can J&J finally put the talc litigation behind it?

Jul 29, 2026, 12:01 PM EDT - 13 days ago

Explainer: Can J&J finally put the talc litigation behind it?

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 4:31 PM EDT - 14 days ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 12:26 PM EDT - 14 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 1:03 AM EDT - 14 days ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

J&J offers $5.5bn to settle baby powder lawsuits

Jul 28, 2026, 12:31 AM EDT - 14 days ago

J&J offers $5.5bn to settle baby powder lawsuits

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 9:29 PM EDT - 14 days ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:47 PM EDT - 14 days ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 6:31 PM EDT - 14 days ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

Jul 27, 2026, 5:45 AM EDT - 15 days ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 23, 2026, 8:30 AM EDT - 19 days ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 4:33 PM EDT - 20 days ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:21 AM EDT - 20 days ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 22, 2026, 7:00 AM EDT - 20 days ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jim Cramer says this old-school investing concept still wins — even in the AI boom

Jul 21, 2026, 6:30 PM EDT - 20 days ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:11 AM EDT - 26 days ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 26 days ago

DePuy Synthes Acquires Expanding Innovations™

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 12:09 PM EDT - 27 days ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 27 days ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 27 days ago

Johnson & Johnson Slides: Q2 2026

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 27 days ago

Johnson & Johnson Earnings release: Q2 2026

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 27 days ago

Johnson & Johnson Quarterly report: Q2 2026

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

Jul 15, 2026, 7:27 AM EDT - 27 days ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 27 days ago

Johnson & Johnson Hikes Guidance, Stock Falls

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 27 days ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:25 AM EDT - 27 days ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:23 AM EDT - 27 days ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 27 days ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 4 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 8, 2026, 7:45 AM EDT - 4 weeks ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jim Cramer says these are the 5 stocks to buy during this market rotation

Jul 6, 2026, 6:29 PM EDT - 5 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 6 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 26, 2026, 12:35 PM EDT - 6 weeks ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 25, 2026, 5:00 AM EDT - 6 weeks ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 2 months ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:41 AM EDT - 2 months ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:33 AM EDT - 2 months ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 11, 2026, 2:03 AM EDT - 2 months ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 11:22 AM EDT - 2 months ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 10, 2026, 6:20 AM EDT - 2 months ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 2 months ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Tnitty4371
Tnitty4371 Aug. 11 at 3:36 PM
$AIHS 🎁🎁🎁💵💵💵📈📈📈 $PLAG $SPY $TSLA $JNJ
0 · Reply
HydrogenH2
HydrogenH2 Aug. 11 at 3:36 PM
$JNJ I guess next will be @ $250 ??
0 · Reply
TraderDaKing
TraderDaKing Aug. 11 at 3:35 PM
$ELTP $PFE $JNJ $LLY $MRNA THIS IS THE NEXT BIG STOCK IN Biopharmaceutical sector. Elite Pharmaceuticals is poised for a strong future with innovative drugs like SequestOx leading the way. Their robust pipeline and commitment to excellence position them as a standout in the pharmaceutical industry. Earnings for the fiscal period will be released Thursday, August 11, 2026. Join the conference call on Friday, August 12, 2026, at 11:30 AM EDT to hear the latest updates directly from the leadership team. For more information, visit their website at https://elitepharma.com/ Elite's ART technology will be the industry standard. ART™, is a multi-particulate capsule that contains an agonist in addition to naltrexone, an antagonist, used primarily in the management of alcohol dependence and drug dependence. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of drugs used today in pain management. ELITE WILL HELP SAVE THE WORLD.
0 · Reply
NRG8
NRG8 Aug. 11 at 3:07 PM
$AVGO $V $MA $JNJ $ABBV
0 · Reply
Wallstfan
Wallstfan Aug. 11 at 2:40 PM
$JNJ some wild price swings of late. Acting like tech stock. Can we just see $270 Geeze
1 · Reply
Matt_1
Matt_1 Aug. 11 at 2:32 PM
$CVRX $GSK $JNJ 👍
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Aug. 11 at 6:32 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
SniperAlphaCom
SniperAlphaCom Aug. 11 at 3:01 AM
$JNJ trade lifecycle update. TS Update #1 was shared with Elite members on June 25, followed by TS Update #2 on July 28. Price respected the updated trailing-stop area near $245, absorbed the pullback, and has now recovered to $261.81. The position remains active. This is why the stop follows structure—not every short-term fluctuation.
0 · Reply
OnlyFibs
OnlyFibs Aug. 11 at 2:19 AM
Johnson & Johnson $JNJ (2h) Bullish Flow: Institutional flow is slamming the Ask across long-dated leaps, including a massive $114.5K split sweep on January 2027 $290 Calls and $35.1K in August $272.50 Calls. Smart money is aggressively accumulating after $JNJ hit the $100.8B full-year revenue milestone while locking in a comprehensive $5.5B talc settlement to remove the primary legal overhang off the balance sheet. 🐂 💧 Bull Key Level: $262.50 (Bull confirmation to break the horizontal consolidation ceiling and launch a macro blue-sky continuation run) 🐂 🔥 Bear Key Level: $252.00 (Key structural support floor and ascending trendline anchor to defend) 🐻 ⚠️ Targets: $275.00 / $290.00 💰 🍺
0 · Reply
LiveTradePro
LiveTradePro Aug. 10 at 11:02 PM
$JNJ Good volume at the close Looks ready https://share.trendspider.com/chart/JNJ/6682nu5lwf
0 · Reply
focafoca99
focafoca99 Aug. 10 at 10:56 PM
$JNJ set to appear at Morgan Stanley's 24th Annual Global Healthcare Conference on Sep 14, with a fireside chat at 11:30 a.m. ET. https://www.rapidticker.com/news/jnj-johnson-amp-johnson-to-participate-8c316e
0 · Reply
TheUnmaker
TheUnmaker Aug. 10 at 8:18 PM
$TNXP Today confirmed the setup with massive over than average volume. Algos re ready to run higher. We will break $14.15 this week and then looking for demand over $16. $PFE $JNJ $GRAL $SLS
1 · Reply
tonyp262
tonyp262 Aug. 10 at 8:01 PM
$JNJ nutty pop at the end there! One of the few pharma’s that have steered away from vaccines which provides a safe haven for healthcare investors amidst the vaccine decision by the current administration
0 · Reply
MessAndGetHorns
MessAndGetHorns Aug. 10 at 7:50 PM
$ESTA Just bought back my shares I trimmed in the upper 80s. Currently holding 500 shares. Breast implants for the win and Motiva is the Queen of the boob job market! $SPY $QQQ $ABBV $JNJ
0 · Reply
Tnitty4371
Tnitty4371 Aug. 10 at 5:54 PM
$ONFO 🎁🎁🎁💵💵💵🎁🎁💵💵💎😎📈📈$SPY $TSLA $META $JNJ
0 · Reply
Orbit100
Orbit100 Aug. 10 at 4:48 PM
$JNJ Funds rotation from the big boys into bio tech stocks.
0 · Reply
Orbit100
Orbit100 Aug. 10 at 4:47 PM
$JNJ Shorts will wake up in the morning and don't know what hit them.
0 · Reply
Orbit100
Orbit100 Aug. 10 at 4:46 PM
$JNJ Ready to soar this week.
0 · Reply
Tnitty4371
Tnitty4371 Aug. 10 at 4:25 PM
$SCKT 💵🎁💎💵🎁💎 $SPY $TSLA $META $JNJ being in the right position at the right time will get you rich 😎
0 · Reply
twiggs462
twiggs462 Aug. 10 at 3:20 PM
$JNJ purchased Janssen Pharmaceuticals, eight years after it was originally founded... 2H of 2027 will be eight years since $DFTX was founded... :)
0 · Reply
Matt_1
Matt_1 Aug. 10 at 3:00 PM
$CVRX $GSK $JNJ 😎👍
0 · Reply
theoptionsplug
theoptionsplug Aug. 10 at 2:59 PM
$JNJ forming a beautiful bull flag on the daily chart Current support sits at $255 which if held, targets at $263 then $270! (50DMA brings an additional layer of support at $250)
0 · Reply